WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2017> 23> 4

Volume: 23 Issue: 4

1. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. Page:340—346
2. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Page:331—339
3. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. Page:323—330
4. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Page:316—322
5. Lamivudine: fading into the mists of time. Page:314—315
6. Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?. Page:311—313
7. Use of sofosbuvir in chronic kidney disease: Is it necessary?. Page:308—310
8. Histopathological evaluation of liver fibrosis and cirrhosis regression. Page:302—307
9. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Page:290—301
10. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 – a review of important differences compared to the CT/MRI system. Page:280—289
11. Treatment options after sorafenib failure in patients with hepatocellular carcinoma. Page:273—279
12. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. Page:265—272

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.